Furthermore, we revealed that CDK1/PBK/CHEK1′s overexpression is associated with poor patient survival in GBM as outlined above in the KM survival estimates, thus underlining the biomarker and prognostic properties of the CDK1/PBK/CHEK1 oncogenic signature in GBM. This evidence concerns the gene CHEK1 and glioblastoma.